[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 实用肝脏病杂志, 2018, 21:177-186.
[2] Rinella ME, Tacke F, Sanyal AJ, et al. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. Hepatology,2019,70:1424-1436.
[3] Applications for FDA Approval to Market a New Drug. 21 CFR 314.500(2019).
[4] US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment draft guidance for industry. https://www.fda.gov/media/119044/download. Published December 2018.
[5] Angulo P, Kleiner DK, Dam-Larsen, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology,2015,149:389-397.
[6] Brunt EM, Kleiner DE, Wilson LA, et al. Improvements in histologic features and diagnosis associatedwith improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials. Hepatology,2019,70:522-531.
[7] Kleiner DE, Brunt EM, Wilson LA, et. al. Association of histologicactivity with progression of nonalcoholic fatty liver disease. JAMA Network Open,2019,2:e1912565-e1912565
[8] Vuppalanchi R, Unalp A, Van Natta ML, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2009,7:481-486.
[9] ICH Expert Working Group. ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions E1. https://database.ich.org/sites/default/files/E1_Guideline.pdf. Published October 27, 1994. Accessed 09/10/2020
[10] US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Compensated cirrhosis related to non-alcoholic steatohepatitis: developing drugs for treatment guidance for industry. https://www.fda.gov/media/127738/download. Published June 2019.Accessed 09/10/2020
[11] Han MAT, Altayar O, Hamdeh S, et al. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol,2019,17:616-629.
[12] Glass O, Filozof C, Noureddin M, et al. Standardization of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. J Hepatol,2020,73: 680-693. |
